8:30 am Morning Coffee & Networking

Chair Day Two: Paola Grandi

Advancing the Delivery of Oncolytic Virotherapies – Intertumoral vs Intravenous Administration

9:00 am Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date

Synopsis

  • Voyager V1 has been administered intravenously to over 100 cancer patients in clinical trials
  • Compelling evidence of single agent activity after a single infusion will be presented

9:30 am Clinical Biomarker Studies with an Enhanced Potency

Synopsis

  • Oncolytic HSV Expressing an Anti-CTLA-4 Antibody as a
  • Single Agent and Combined with Nivolumab in Patients with
  • Advanced Solid Tumors Indicates Potent Immune Activation

10:00 am Allogeneic Stem Cell-Based Platforms to Potentiate and Deliver Oncolytic Virus Therapies

  • Boris Minev President, Medical & Scientific Affairs, Calidi Biotherapeutics

Synopsis

  • Shortcomings of unprotected oncolytic virus therapies
  • Advantages of Calidi’s stem cell-based platforms for potentiation of oncolytic virotherapies – preclinical data
  • Calidi’s clinical programs

10:30 am Clinical Trials of Oncolytic Virotherapy for Brain Tumors

  • Antonio Chiocca Chairman, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School

Synopsis

  • Define how OV’s change the tumor microenvironment
  • Review current status of clinical trials in brain tumors
  • Focus on future avenues of research

11:00 am Morning Break & Refreshments

Navigating the Landscape – Investment, Regulatory Guidelines & Partnering

12:00 pm Panel Discussion: Navigating the Field of Oncolytic Virus Partnering & Investment

  • Natalia Ulyanova Director Oncology Business Development, Search & Evaluation, Astellas
  • Enoch Yue Associate Director, Business Development Oncology Search & Evaluation, Bristol Myers Squibb
  • Karen Ann Cherkis Senior Director Search & Evaluation, Bristol Myers Squibb
  • Patrik Erlmann Head of Research Beyond Borders, Boehringer Ingelhiem

Synopsis

Understand the Necessary Parameters for An Attractive Potential New Partner in The Field of Oncolytic Viruses with Examples from The Field

  • What are the fundamental assets a biotech must have when approaching large pharma for a potential licensing agreement or acquisition proposition?
  • Acquisition vs Licensing: Is there a preferential route for large pharma?
  • Where will future innovation come from within the field of oncolytic viruses?

12:30 pm Lunch Break & Networking

Insights from Within the Clinic: Demonstrating the New Generation of Oncolytic Viruses

2:00 pm Clinical Update & Lessons Learned with Talimogene Laherparepvec in Solid Tumor Oncology

  • Austin Nuschke Senior Medical Scientist, Solid Tumor Oncology, Amgen

2:30 pm Rationale Design of Phase 1 Trial Combining Oncolytic Virotherapy with CAR-T Cells

  • Neil Sheppard Director & Head T Cell Engineering Lab, University of Pennsylvania Center for Cellular Immunotherapies

Synopsis

  • CAR-T therapy of solid tumors is limited by tumor microenvironments that exclude and suppress T cells such as huCART-meso cells targeting mesothelin
  • VCN-01, a PH20 hyaluronidase-armed Oncolytic Virus degrades tumor extracellular matrix, reprograms the tumor microenvironment, and draws T cells into tumor lesions
  • We designed a combination trial NCT05057715 to establish the safety, feasibility, and preliminary efficacy of a combination of huCART-meso cells and VCN-01 in patients with pancreatic or ovarian cancer

3:00 pm Oncolytic Viral Immunotherapy For Hard-To-Treat Solid Tumors

  • Paul Peter Tak President & Chief Executive Officer, Candel Therapeutics

Synopsis

  • Introduction to oncolytic viral immunotherapy as a new approach to induce a specific immune response against the injected solid tumor and uninjected distant metastases
  • Clinical and immunological data showing the effects of experimental treatment with CAN-2409 in combination with immune checkpoint inhibitors (ICI) in patients with stage III/IV NSCLC who had an inadequate response to ICI as well treatment with CAN-2409 in combination with nivolumab and first-line standard of care in patients with high-grade glioma
  • Clinical and immunological data showing the effects of CAN-3110 in patients with recurrent high-grade glioma

3:30 pm End of 7th Oncolytic Virotherapy Summit 2022